PA
NKTR icon

Profund Advisors’s Nektar Therapeutics NKTR Stock Holding History

Profund Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$227K Buy
+3,159
New +$180K 0.01% 945
2023
Q2 		– Sell
-794
Closed -$8.37K – 1110
2023
Q1 		$8.37K Sell
794
-89
-10% -$2.69K ﹤0.01% 1087
2022
Q4 		$29.9K Sell
883
-71
-7% -$3.44K ﹤0.01% 998
2022
Q3 		$46K Sell
954
-1,513
-61% -$90K ﹤0.01% 909
2022
Q2 		$141K Sell
2,467
-102
-4% -$6.44K 0.01% 950
2022
Q1 		$208K Buy
2,569
+27
+1% +$4K 0.01% 1240
2021
Q4 		$515K Sell
2,542
-8
-0.3% -$1.74K 0.02% 593
2021
Q3 		$687K Sell
2,550
-190
-7% -$45.7K 0.02% 489
2021
Q2 		$704K Sell
2,740
-53
-2% -$14.7K 0.02% 488
2021
Q1 		$838K Sell
2,793
-255
-8% -$79.4K 0.03% 364
2020
Q4 		$777K Buy
3,048
+257
+9% +$66.4K 0.03% 383
2020
Q3 		$695K Sell
2,791
-307
-10% -$96.6K 0.04% 366
2020
Q2 		$1.08M Buy
3,098
+501
+19% +$156K 0.06% 255
2020
Q1 		$695K Sell
2,597
-1,152
-31% -$356K 0.05% 292
2019
Q4 		$1.21M Buy
3,749
+932
+33% +$270K 0.05% 303
2019
Q3 		$770K Sell
2,817
-192
-6% -$70.4K 0.04% 416
2019
Q2 		$1.61M Sell
3,009
-332
-10% -$166K 0.08% 253
2019
Q1 		$1.68M Buy
3,341
+81
+2% +$48K 0.08% 224
2018
Q4 		$1.61M Sell
3,260
-847
-21% -$511K 0.1% 195
2018
Q3 		$3.75M Buy
4,107
+615
+18% +$525K 0.14% 119
2018
Q2 		$2.56M Sell
3,492
-552
-14% -$637K 0.1% 159
2018
Q1 		$6.45M Sell
4,044
-1,352
-25% -$1.74M 0.26% 59
2017
Q4 		$4.83M Sell
5,396
-440
-8% -$260K 0.19% 90
2017
Q3 		$2.1M Buy
5,836
+4,066
+230% +$1.27M 0.09% 210
2017
Q2 		$519K Sell
1,770
-125
-7% -$36.1K 0.02% 709
2017
Q1 		$667K Sell
1,895
-454
-19% -$102K 0.03% 666
2016
Q4 		$432K Buy
2,349
+953
+68% +$194K 0.02% 1005
2016
Q3 		$360K Buy
1,396
+221
+19% +$56.9K 0.02% 980
2016
Q2 		$251K Sell
1,175
-79
-6% -$17.7K 0.01% 1229
2016
Q1 		$259K Sell
1,254
-434
-26% -$83.4K 0.01% 1186
2015
Q4 		$427K Buy
1,688
+312
+23% +$64.2K 0.02% 730
2015
Q3 		$226K Sell
1,376
-770
-36% -$136K 0.01% 1029
2015
Q2 		$403K Buy
+2,146
New +$369K 0.02% 911
2014
Q3 		– Sell
-5,628
Closed -$1.08M – 1409
2014
Q2 		$1.08M Sell
5,628
-1,286
-19% -$227K 0.05% 439
2014
Q1 		$1.26M Buy
6,914
+1,840
+36% +$364K 0.06% 353
2013
Q4 		$864K Buy
5,074
+1,030
+25% +$166K 0.04% 621
2013
Q3 		$634K Buy
4,044
+188
+5% +$34.8K 0.03% 762
2013
Q2 		$668K Buy
+3,856
New +$591K 0.05% 463

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Profund Advisors's NKTR Position: Q1 2026 in Review

Profund Advisors opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 3,159 shares worth $227K. The stake represents 0.01% of the portfolio and ranks #945 among its holdings. This is a return to the name: Profund Advisors previously reported a position in NKTR as recently as Q1 2023.

Profund Advisors first reported a position in NKTR in Q2 2013 and has held it in 38 quarters since. The position peaked at $6.45M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Profund Advisors held 3,159 shares of Nektar Therapeutics worth $227K as of Q1 2026.
  • Nektar Therapeutics was a new Profund Advisors position in Q1 2026.
  • Nektar Therapeutics made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #945 holding.
  • Profund Advisors first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 38 quarters since.
  • Profund Advisors's Nektar Therapeutics position peaked at $6.45M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.